|Min SIP Amount||Not Supported|
|NAV||₹8.16 (28 Sep 2020)|
|Fund Started||21 Dec 2017|
|Fund Size||₹135 Cr|
|Bayer CropScience Ltd.||Healthcare||Equity||6.0%|
|Balrampur Chini Mills Ltd.||FMCG||Equity||5.6%|
|CreditAccess Grameen Ltd.||Financial||Equity||5.6%|
|Procter & Gamble Health Ltd.||Healthcare||Equity||5.2%|
|Valiant organics Ltd||Healthcare||Equity||5.1%|
|Birla Corporation Ltd.||Construction||Equity||4.8%|
|Indian Energy Exchange Ltd.||Financial||Equity||3.6%|
Nippon India Capital Builder Fund IV Series C Direct Growth is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 21 Dec 2017. Samir Rachh, Jahnvee Shah, Meenakshi Dawar, Dhrumil Shah is the Current Fund Manager of Nippon India Capital Builder Fund IV Series C Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹135 Cr and the Latest NAV as of 28 Sep 2020 is ₹8.16.
The Nippon India Capital Builder Fund IV Series C Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 500.
The scheme seeks to provide capital appreciation to the investors, which will be in line with their long term savings